# 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

Source: https://onco.cc/trials/nct03849118/  
OnCo record `nct03849118` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of CAIX PET in Clear cell renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, completed.

## Summary

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study is a phase 3 interventional study registered as NCT03849118 by Telix Pharmaceuticals (Innovations) Pty Limited, with 300 participants recorded, started 2019-08-15 and reaching its primary completion in 2022-10-20. Interventions recorded: 89Zr-girentuximab. Conditions recorded: Clear Cell Renal Cell Carcinoma.

Linked to the technology CAIX PET because the registry names it ("89zr girentuximab") among its interventions and Clear cell renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03849118
- Phase: 3
- Setting: A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
- Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT03849118: https://clinicaltrials.gov/study/NCT03849118

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/)
- technologies: [CAIX PET (89Zr-girentuximab)](https://onco.cc/technologies/caix-pet/)

---
JSON: https://onco.cc/api/v1/entities/nct03849118.json